UK Markets closed

Immunicum AB (publ) (IMMU.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
3.7800+0.1000 (+2.72%)
At close: 05:24PM CET
Full screen
Previous close4.8350
Open3.6000
Bid3.9950 x 0
Ask4.0150 x 0
Day's range3.3900 - 4.2800
52-week range3.1700 - 9.3700
Volume4,697,890
Avg. volume507,827
Market cap628.111M
Beta (5Y monthly)0.97
PE ratio (TTM)N/A
EPS (TTM)-1.1710
Earnings date18 Feb 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.70
  • Globe Newswire

    Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study

    Press Release Stockholm, Sweden, December 3, 2021 Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study Immunicum AB (“Immunicum”, publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today the completion of the Phase Ib portion of the ILIAD study evaluating the Company’s off-the-shelf, cell-based immune primer ilixadencel in combination with anti-PD1 checkpoint inhibitor (CPI) pem

  • Globe Newswire

    Immunicum and PCI Biotech Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments

    Press Release Stockholm, Sweden, November 30, 2021 Immunicum and PCI Biotech Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, and PCI Biotech Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation, announced to

  • Globe Newswire

    Immunicum Publishes DCP-001 Mechanism of Action in the Journal Cells

    Press ReleaseStockholm, Sweden, November 22, 2021Immunicum Publishes DCP-001 Mechanism of Action in the Journal CellsImmunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today the publication of a scientific journal article describing the mechanism of action for its cell-based cancer relapse vaccine DCP-001. The publication in the peer-reviewed journal Cells details the interaction between DCP-001